The use of eculizumab in gemcitabine induced thrombotic microangiopathy

BACKGROUND: Thrombotic microangiopathy (TMA) secondary to gemcitabine therapy (GiTMA) is a very rare pathology that carries a poor prognosis, with nearly half of the cases progressing to end stage renal disease. GiTMA is most commonly associated with adenocarcinomas, most notably pancreatic cancers....

Descripción completa

Detalles Bibliográficos
Autores principales: Krishnappa, Vinod, Gupta, Mohit, Shah, Haikoo, Das, Abhijit, Tanphaichitr, Natthavat, Novak, Robert, Raina, Rupesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767063/
https://www.ncbi.nlm.nih.gov/pubmed/29329518
http://dx.doi.org/10.1186/s12882-018-0812-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767063/
https://www.ncbi.nlm.nih.gov/pubmed/29329518
http://dx.doi.org/10.1186/s12882-018-0812-x

Ejemplares similares